The efficacy of targeting the PI3K/AKT pathway directly (e.g., by mTOR inhibitor everolimus) has been tested mostly for the treatment of glioblastoma, but did not show additional survival benefit in a phase II trial [262]. Here, AKT1 is linked to glioblastoma.